Registration Info

Webinar Registration

This is a half-day meeting and will provide 3 CE/CME credits.


Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.

To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

Saturday, May 16, 2020

  • Introductions and CE/CME Instructions

  • The Other Opioid Crisis: Heroin and Fentanyl

    There is a significant amount of media, political, and public attention paid to the opioid crisis/opioid epidemic in the United States today. With the seemingly ever-increasing number of opioid-related overdoses and fatalities, there has been a feverish push by stakeholders to diminish the amount of opioids prescribed in order to help stem these worrisome trends. Unfortunately, there may be a lack of focus regarding the true definition and characterization of the opioid epidemic. There may also be a rush to judgment about the role of appropriately prescribed opioid analgesics in the addiction crisis we face today as well. This presentation will discuss the roles and statistics of both prescription and illicit opioids (namely heroin and fentanyl) in today’s “opioid overdose epidemic” with the intention of clarifying important differences and similarities between these competing epidemics including concerns and clinical considerations specific to each of them. Additionally, this program will examine and identify how these medications and drugs share potentially tragic adverse effect profiles in many cases. However, it is important for clinicians to make sure that appropriate chronic pain patients that may be candidates for opioid analgesic therapy aren’t penalized, and still get the treatment that they deserve.

    • UAN: 0530-0000-20-044-L04-P
    • AANP Rx Hours: 0.00
  • Mirror Mirror on the Wall: Who's the FDA's Fairest ADF of All?

    Challenge accepted. Our country has made numerous strides in advancing patient care, and more particularly conducting efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit (and possibly laced) diacetylmorphine (aka heroin). How do these formulations work, one might ask? Which ADF opioid medications are not only available on the us market, but also specifically approved as an ADF opioid medication? Are these ADFs really foolproof? Well, the street chemists of our country have already accepted the challenge to be knowledgeable on all of the above. Now it’s our turn as healthcare professionals to get up to speed on these risk reduction entities.

    • UAN: 0530-0000-20-042-L04-P
    • AANP Rx Hours: 0.80
  • Drugs, Documentation, and DEA: Improving Your Charting of Prescribing Rationale in 2020 and Beyond

    Overlooking the importance of carefully documenting the rationale for the use of a controlled medication can land a prescriber in hot water with their licensing board or the DEA. This course will focus on what it takes to move beyond the problems associated with both EMR and handwritten medical charts, and into the documentation of cogent notes signaling proper patient evaluation, including risk evaluation, rationale for the use of controlled medication, and ongoing encounters with the patient.

    • UAN: 0530-0000-20-027-L03-P
    • AANP Rx Hours: 0.00
  • Faculty Q&A